Samsung Seeks To Scrub US Soliris Patents With A Pair Of USPTO Challenges
Small Pool Of Eculizumab Biosimilar Developers Includes Settler Amgen
Executive Summary
Samsung Bioepis has taken to five its number of IPR challenges to Alexion’s US Soliris intellectual property portfolio, filing two simultaneously.